Akiram Therapeutics

Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.

akiramtherapeutics.se
LinkedIn

Press release:
Sciety invests in a company developing targeted radioimmunotherapy for incurable cancer